



Asamedic
Dedicated to saving lives

Asamedic AS out-licenses commercialization rights of Coxor® in the Nordics to Evolan Pharma AB

July 5, 2022. Asamedic AS today announced that it has entered into an agreement with Evolan Pharma AB for the exclusive rights to Coxor® (300mg Acetylsalicylic Acid) in the Nordic countries.

Coxor® received marketing authorization in Norway and Denmark through the European DCP. Mutual Recognition Procedure is available to extend this to the rest of Europe.

Evolan Pharma adds Coxor® to its portfolio to bring benefit to patients by addressing a significant unmet need in the treatment of Acute Myocardial Infarction (AMI) and will hold exclusive rights to Coxor™ in Norway, Sweden, Denmark, Finland and Iceland.

Geir Ivar Westen, CEO at Asamedic, added: *“This agreement is a part of our work toward saving lives and will ultimately provide better prospects for patients attacked by AMI in the Nordics. Evolan Pharma has a long track record and expertise in the Nordic region and is well placed to provide Coxor® to the population. We are looking forward to working closely with Evolan for a long time to come.”*

Richard Karroum, CEO of Evolan Pharma commented: *“By partnering with Asamedic on Coxor®, we continue to serve our purpose to address significant medical needs. With our products we have built a high level of expertise in the cardiovascular space which will allow us to market Coxor successfully”.*

About Asamedic AS

Asamedic, a Norwegian company established in 2013, aims to reduce mortality from heart attack, saving lives through research and innovation. Asamedic has 81 shareholders, many of them from within the medical field. Asamedic focuses solely on AMI and Coxor®, and the product has been awarded patents in many countries around the world, including entire Europe and the United States. You can read more about Asamedic at www.asamedic.no.

About Evolan Pharma AB

Evolan Pharma AB is a privately owned Swedish pharmaceutical company with operations in the Nordic countries that brings extensive knowledge from the pharmaceutical area. Its competences are concentrated around business development, marketing and sales of pharmaceutical products. To ensure high quality and availability of its products Evolan Pharma partners with well-established producers and service providers. The company is experiencing strong growth, with many new products in registration and launch phase.

About Coxor®

Coxor® consists of powder and solvent for oral solution for emergency treatment for suspected Acute Myocardial Infarction. This medicine is used in adults for suspected AMI (heart attack). Upon administration, powder is released into a tailored liquid solution to provide quick dissolution of the medicine for rapid onset-of-action. This is vital when treating AMI. You can read more about Coxor® on www.asamedic.no

LifeSci Consulting serves as the transaction advisor to Asamedic <https://lifesciconsulting.com/>